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Design of the liraglutide effect and action in diabetes:
Evaluation of cardiovascular outcome results
(LEADER) trial
Steven P. Marso, MD, a,m Neil R. Poulter, FRCP, b,m Steven E. Nissen, MD, c,m Michael A. Nauck, MD, d,m
Bernard Zinman, MD, e,m Gilbert H. Daniels, MD, f,m Stuart Pocock, PhD, g,m William M. Steinberg, MD, h,m
Richard M. Bergenstal, MD, i,m Johannes F. E. Mann, MD, j,m Lasse Steen Ravn, MD, PhD, k,m
Kirstine Brown Frandsen, MD, k,m Alan C. Moses, MD, k,m and John B. Buse, MD, PhD l,m Kansas City, Missouri;
London, United Kingdom; Cleveland, OH; Lauterberg, and Erlangen, Germany; Toronto, Canada; Boston, MA;
Rockville, MD; Minneapolis, MN; Bagsvaerd, DE; and Chapel Hill, NC
Background Diabetes is a multisystem disorder associated with a nearly twofold excess risk for a broad range of
adverse cardiovascular outcomes including coronary heart disease, stroke, and cardiovascular death. Liraglutide is a human
glucagon-like peptide receptor analog approved for use in patients with type 2 diabetes mellitus (T2DM).
Study Design To formally assess the cardiovascular safety of liraglutide, the Liraglutide Effect and Action in Diabetes:
Evaluation of cardiovascular outcome Results (LEADER) trial was commenced in 2010. LEADER is a phase 3B, multicenter,
international, randomized, double-blind, placebo-controlled clinical trial with long-term follow-up. Patients with T2DM at high
risk for cardiovascular disease (CVD) who were either drug naive or treated with oral antihyperglycemic agents or selected
insulin regimens (human NPH, long-acting analog, or premixed) alone or in combination with oral antihyperglycemics were
eligible for inclusion. Randomized patients are being followed for up to 5 years. The primary end point is the time from
randomization to a composite outcome consisting of the first occurrence of cardiovascular death, nonfatal myocardial
infarction, or nonfatal stroke.
Conclusions LEADER commenced in September 2010, and enrollment concluded in April 2012. There were 9,340
patients enrolled at 410 sites in 32 countries. The mean age of patients was 64.3 ± 7.2 years, 64.3% were men, and mean
body mass index was 32.5 ± 6.3 kg/m2. There were 7,592 (81.3%) patients with prior CVD and 1,748 (18.7%) who
were high risk but without prior CVD. It is expected that LEADER will provide conclusive data regarding the cardiovascular
safety of liraglutide relative to the current standard of usual care for a global population of patients with T2DM. (Am Heart J
2013;166:823-830.e5.)
Background
Diabetes mellitus affects nearly 350 million people
worldwide,1 including 26 million patients in the United
States,2 and the prevalence continues to increase.
Diabetes is a chronic disease associated with long-term
vascular complications. Type 2 diabetes mellitus (T2DM)
is a multisystem disorder that is also independently
associated with a nearly twofold excess risk for a broad
range of adverse cardiovascular outcomes including
coronary heart disease (CHD), stroke, and cardiovascular
death. Subgroups of individuals with diabetes at lower
absolute risk of cardiovascular complications, including
women, younger persons, nonsmokers, and persons with
below average blood pressure, also have an elevated risk
of micro- and macrovascular complications (including
CHD), compared with persons without diabetes.3
Effective strategies to mitigate cardiovascular risk and
prevent or reduce the occurrence of microvascular
complications are the cornerstone of treatment for
patients with diabetes.4 These measures include lifestyle
management, smoking cessation, and individualized risk
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factor treatment for low-density lipoprotein cholesterol
and blood pressure. Glycemic control significantly re-
duces the development and progression of microvascular
complications. Although metformin is the mainstay of
initial therapy, treatment with a glucagon-like peptide-1
(GLP-1) receptor agonist is now regularly used as an add-
on approach to achieve glycemic control.5
Although available diabetes therapies clearly improve
glycemic control, the cardiovascular safety of particular
glucose-lowering agents is controversial. When cardiovas-
cular safety concerns were identified in an agonist of the
peroxisome proliferator–activated receptor gamma class,6
as well as in a separate federally funded study examining
tight glycemic control in general,7 the United States Food
and Drug Administration subsequently issued mandatory
guidelines to manufacturers for evaluating the cardiovas-
cular safety of emerging therapies to treat diabetes.8 Before
new diabetes drug approval, manufacturers are now
required to perform an integrated meta-analysis of
completed studies to demonstrate an estimated relative
risk with upper two-sided 95% confidence limits for major
adverse cardiovascular events of b1.8 versus comparators.
If the upper limit is 1.3 to 1.8, safety must subsequently be
demonstrated in postmarketing cardiovascular outcome
trials to rule out an upper confidence limit of 1.3.
Glucagon-like peptide-1 and liraglutide. Native GLP-1
is an incretin hormone produced in the gut and secreted
in response to food consumption.9 The main pharmaco-
logical effects of GLP-1 are stimulation of endogenous
insulin in response to elevated glucose, suppression of
elevated glucagon, and regulation of satiety/appetite10,11
and are all potentially beneficial or impaired in T2DM.
Liraglutide is an analog of human GLP-1 approved for
use in patients with T2DM. Liraglutide has 97% homology
with human GLP-1 and is administered subcutaneously
once daily. Its glucose-lowering efficacy has been
established, and its use results in hemoglobin A1c
(HbA1c) reductions of 1.0 to 1.5% in addition to moderate
weight loss across a wide range of patient types.12 To
formally assess the cardiovascular safety of liraglutide, the
Liraglutide Effect and Action in Diabetes: Evaluation of
cardiovascular outcome Results (LEADER) trial (clinical-
trials.gov NCT01179048) was commenced in 2010. This
article reports the study design and baseline characteris-
tics of the study population.
Study design
Objective. The primary objective of LEADER is to
assess the effect of treatment with liraglutide compared to
placebo (for at least 3.5 years and up to 5 years) on the
incidence of cardiovascular events, as defined by the
primary end point of cardiovascular death, nonfatal
myocardial infarction (MI), or nonfatal stroke in adult
patients with T2DM. The primary analysis will be
noninferiority testing. If the prespecified noninferiority
criteria are met, then superiority testing will be per-
formed. Noninferiority of liraglutide versus placebo will
be assessed by inspecting the upper range of the two-
sided 95% CI, and noninferiority will be established if that
upper range is b1.3. Only if noninferiority is established
for the primary outcome will the data then be used to test
for evidence of a lower outcome hazard with liraglutide
over placebo. Superiority will be established if the hazard
ratio of the upper range of the two-sided 95% CI is b1.0.
This approaches a closed testing procedure, and there-
fore, no adjustment of the significance level is required.
Patient population. LEADER is a phase 3B, multi-
center, international, randomized, double-blind, place-
bo-controlled clinical trial with long-term follow-up
(Figure 1). Male and female patients with T2DM, who
were either drug naive or treated with oral antihyper-
glycemic agents or selected insulin regimens (human
NPH, long-acting analog, or premixed) alone or in
combination with oral antihyperglycemics were eligible
for inclusion.
LEADER enrolled 2 distinct populations of high-risk
patients either with or without prior cardiovascular
disease (CVD): (1) patients with prior CVD were ≥50
years old and had one or more of the following
cardiovascular comorbidities (detailed criteria are
shown in Table I): concomitant CVD, cerebrovascular
disease, peripheral vascular disease, chronic renal
failure, or chronic heart failure; (2) patients without
prior CVD were ≥60 years old at screening and had one
or more cardiovascular risk factors shown in Table I.
Enrollment of approximately 400 patients with moderate
(30-59 mL/min per 1.73 m2) and 200 patients with
severe (b30 mL/min per 1.73 m2) reductions in baseline
estimated glomerular filtration rate (eGFR) as estimated
using the Modification of Diet in Renal Disease (MDRD)
Figure 1
LEADER study design.
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equation was also prespecified. Exclusion criteria are
listed in Table I.
Treatment regimen. After eligibility assessment and
informed consent, patients completed a minimum 2-
week run-in period consisting of a daily single-blind
subcutaneous injection of placebo. Patients demonstrat-
ing ≥50% adherence to the regimen and willingness to
continue with the injection protocol throughout the trial
then underwent randomization, which was carried out
for all subjects using the interactive voice/web response
system. Subjects meeting all inclusion/exclusion criteria
were randomized in a 1:1 manner to receive a double-
blind, once-daily maximum dose of liraglutide 1.8 mg or
equivalent placebo as an add-on to their standard-of-care
treatment. Liraglutide was administered at 0.6 mg daily
for 1 week, 1.2 mg for an additional week, and a potential
maximum dosage thereafter of 1.8 mg based on
tolerance, as determined by the investigator.
For patients with suboptimal glucose control after
randomization, concomitant use and dosage of insulin,
sulfonylureas, glimepiride, thiazolidinediones, and α-
glucosidase inhibitors is permitted at the discretion of
the investigator, but use of other GLP-1 agonists,
dipeptidyl peptidase-4 inhibitors, and pramlintide is not.
Concomitant use of premixed insulin. Continued
use of premixed insulin, including injection frequency
and timing, during the trial is permitted at the investiga-
tor's discretion. A 20% reduction in insulin dosage when
starting randomized therapy is recommended for patients
with HbA1c ≤8%.
The LEADER global expert panel (GEP) and national
study leaders in participating countries developed a
protocol for the treatment of risk factors and concomitant
use of medications. Guidelines were finalized during a
series of workshops using consensus practice recom-
mendations in 2010.13–16 Table II contains a list of the
finalized standard of care guidelines endorsed by the
LEADER steering committee.
Planned follow-up. After randomization, patients
were initially seen at 1, 3, and 6 months. Thereafter,
patients are seen every 6 months for up to 5 years. During
each study visit, patients are assessed for clinical events,
study drug compliance, and concomitant medication
Table I. LEADER Inclusions and Exclusions
Inclusion criteria
● Type 2 diabetes
● Anti-diabetic drug naïve or treated with one or more oral anti-diabetic
drugs or treated with human NPH insulin or long-acting insulin
analogue or premixed insulin, alone or in combination with OAD(s)
● HbA1c ≥7.0%
● Prior CVD cohort: age ≥50 and ≥1 of the following criteria.
○ Prior MI
○ Prior stroke or TIA
○ Prior coronary, carotid or peripheral arterial revascularization
○ N50% stenosis of coronary, carotid, or lower extremity arteries
○ History of symptomatic CHD documented by Positive exercise stress
test or any cardiac imaging or Unstable angina with ECG changes
○ Asymptomatic cardiac ischemia
Documented by positive nuclear imaging test, exercise test or
dobutamine stress echo
○ Chronic heart failure NYHA class II-III
○ Chronic renal failure,
eGFR b60 mL/min per 1.73m2 MDRD
eGFR b60 mL/min per Cockcroft-Gault formula
● No Prior CVD group: Age ≥60 y and ≥1 of the following criteria.
○ Microalbuminuria or proteinuria
○ Hypertension and left ventricular hypertrophy by ECG or imaging
○ Left ventricular systolic or diastolic dysfunction by imaging
○ Ankle-brachial index b0.9
Exclusion criteria
● Type 1 diabetes
● Calcitonin ≥50 ng/L
● Use of a GLP-1 receptor agonist (exenatide, liraglutide or other) or
pramlintide or any DPP-4 inhibitor within the 3 months prior to screening
● Use of insulin other than human NPH insulin or long-acting insulin
analogue or premixed insulin within 3 months prior to screening. Short-
term use of other insulin during this period in connection with
intercurrent illness is allowed, at Investigators discretion
● Acute decompensation of glycemic control
● An acute coronary or cerebrovascular event in the previous 14 d
● Currently planned coronary, carotid, or peripheral artery
revascularization
● Chronic heart failure (NYHA class IV)
● Current continuous renal replacement therapy
● End-stage liver disease
● History of solid organ transplant or awaiting solid organ transplant
● Malignant neoplasm
● Family or personal history of multiple endocrine neoplasia type 2
(MEN2) or familial medullary thyroid carcinoma (FMTC)
● Personal history of non-familial medullary thyroid carcinoma
Table II. Standard of Care Guidelines for LEADER
Blood glucose
● HbA1c ≤7.0% (individualized depending on patient).
● If N7.0%, additional HbA1c measurement after 3 m. If HbA1c still
N7.0%, treatment should be intensified to achieve target if appropriate.
Therapy
● Lifestyle modifications and metformin are considered foundational
therapy in most countries
● Intensification:
○ Add-on therapy: thiazolidinediones, sulfonylureas, α-glucosidase
inhibitors, according to local labels (dipeptidyl peptidase-4 inhibitors
and other incretin based therapies are not allowed)
○ Insulin therapy should be based on local practice, including basal,
basal/bolus, premix, and mealtime bolus (SIT)
Blood pressure
○ Target: 130/80 mm Hg
Antihypertensive therapy
● First line: ACE inhibitors or ARBs
● Based on individual patient needs: Ca2+−blockers, diuretics, others
Lipid targets and therapy
● LDL b100 mg/dL (b70 mg/dL in patients with previous cardiovascular
events)
● Statins recommended for all patients
● Second line therapy at investigator discretion
Antiplatelet therapy
● Aspirin or clopidogrel (if aspirin intolerant) for patients with prior
cardiovascular events (MI, cerebrovascular accident,
or revascularization)
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usage. Blood, urine specimens, and electrocardiograms
were collected at randomization and then yearly for the
duration of the study.
End points. The primary end point is the time from
randomization to a composite outcome consisting of
the first occurrence of cardiovascular death, nonfatal
MI, or nonfatal stroke. Comprehensive descriptions for
each component of the primary composite end point
are listed in the online Appendix Supplementary Table
I. Secondary end points include the first occurrence of
an expanded composite cardiovascular outcome, in-
cluding cardiovascular death, nonfatal MI, nonfatal
stroke, revascularization, hospitalization for unstable
angina, or hospitalization for chronic heart failure.
Additional end points include time from randomization
to the occurrence of noncardiovascular or all-cause
death, each individual component of the expanded
composite cardiovascular outcome, composite micro-
vascular outcomes, and each individual component of
composite microvascular outcomes.
Safety end points. Additional end points are being
assessed to support the secondary efficacy and safety
objectives (online Appendix Supplementary Table II).
Hypoglycemia is defined according to American Diabe-
tes Association criteria17 as (1) severe: requiring the
assistance of another person to administer resuscitative
actions, carbohydrate, or glucagon; (2) documented
symptomatic: typical symptoms of hypoglycemia ac-
companied by a measured plasma glucose concentration
≤70 mg/dL; (3) asymptomatic: measured plasma glucose
concentration ≤70 mg/dL in the absence of symptoms;
(4) probable symptomatic: unmeasured plasma glucose
concentration in the presence of typical symptoms of
hypoglycemia; and (5) relative hypoglycemia: typical
symptoms of hypoglycemia and interpreted by the
patient as a hypoglycemic episode with a measured
plasma glucose concentration ≥70 mg/dL. An indepen-
dent, event adjudication committee (EAC) blinded to
treatment arm will adjudicate serious adverse events,
including pancreatitis or severe persistent abdominal
pain leading to suspicion of pancreatitis, neoplasm, and
thyroid disease resulting in thyroidectomy (online
Appendix Supplementary Table II).
Calcitonin monitoring. Blood samples were collect-
ed at screening to assess baseline levels of calcitonin in
a central laboratory; patients with values ≥50 ng/L were
excluded. Calcitonin levels are measured at prespecified
time intervals in all subjects throughout the study. An
independent calcitonin-monitoring committee (CMC)
consisting of thyroid experts blinded to treatment
provides ongoing surveillance to monitor longitudinal
changes in calcitonin levels. Any value ≥20 ng/L is
reported to the CMC for review and consideration of
additional diagnostic procedures. For any level ≥20 ng/L,
testing is repeated within 4 weeks. If the level is
confirmed, a medical event of special interest is
reported, and the CMC provides guidance on individu-
alized follow-up and/or subsequent monitoring to site
investigators. All medical events of special interest,
including development of neoplasm or thyroid disease
resulting in thyroidectomy, are reviewed and adjudicated
by the EAC.
Study organization, event adjudication, and data
monitoring. LEADER is overseen by a steering committee
composed of experts in endocrinology, cardiology,
gastroenterology, thyroid disease, nephrology, biostatis-
tics, and employees of the study sponsor (Novo Nordisk).
The steering committee independently oversees all
aspects of the trial. The GEP consists of principal
investigators from enrolling countries and designated
employees of the sponsor and provides advice and active
implementation assistance for operational issues.
Several end points will be adjudicated by the EAC based
on several efficacy end points, including death, acute
coronary syndrome (MI and hospitalization for unstable
angina), cerebrovascular events (stroke and transient
ischemic attack), coronary revascularization procedures,
hospitalization for heart failure, nephropathy, and dia-
betic retinopathy.
The EAC consists of experts in cardiology, neurology,
gastroenterology, endocrinology, oncology, pathology,
nephrology, and ophthalmology and will meet through-
out the duration of the trial. A chairperson oversees 4
separate subcommittees consisting of 16 primary adjudi-
cators. The cardiovascular subcommittee includes 2
cardiologists and 2 neurologists. The microvascular
subcommittee includes 2 nephrologists and 2 ophthal-
mologists. The pancreatitis subcommittee includes 3
gastroenterologists. The neoplasm subcommittee in-
cludes 3 oncologists and 2 endocrinologists. In case of
thyroid disease resulting in a thyroidectomy, adjudicators
include 1 endocrinologist and 1 oncologist who will
review both the local pathology report and the report of
an external pathologist who has reviewed the pathology
specimen independently.
An independent, external data-monitoring committee
(DMC) was established to perform ongoing safety
surveillance and consists of permanent members who
are recognized experts in cardiology, endocrinology,
gastroenterology, and statistics. The DMC has access to
complete unblinded data and meets at predefined
intervals and on an ad hoc basis as required to evaluate
all relevant safety information. After each meeting, the
DMC will issue a recommendation on trial continuation,
modification, or termination. The DMC can recommend
to terminate the trial prematurely in case there is
evidence for an excess number of deaths in the liraglutide
group (significance level determined at P b .01), an
excess number of major adverse cardiovascular events in
the liraglutide group (significance level determined at P b
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.01), or clear evidence of benefit for the primary end
point in the liraglutide arm (significance level determined
at P b .001).
Funding
The LEADER trial was funded by Novo Nordisk. No
extramural funding was used to support the creation
of this article. The authors are solely responsible for
the design and conduct of this study, all study
analyses, and the drafting and editing of the paper
and its final contents.
Statistical considerations
Sample size calculation. The required sample size
was estimated on the basis of time to first primary
outcome using a log-rank test that included the full
analysis set and an intention-to-treat principle. The
primary event rate was estimated to be 1.8% in both
the liraglutide and placebo groups, with uniform
enrollment over 1.5 years, and a maximum follow-up
period of 5 years. The noninferiority margin was set
at 1.3 for the upper bound of the 2-sided 95% CI. It
was also estimated that patients who permanently
stop randomized treatment and are lost to follow-up
would not exceed 10% in total. Finally, the power to
reject the null hypothesis (ie, that the upper bound of
the 2-sided CI would exceed 1.3) was set at 90%.
Given these assumptions, 8,754 randomized subjects
were required with an accrual of no b611 events
with a minimum follow-up of 42 months after last
subject randomized.
Analysis of the primary end point. Only outcomes
confirmed by the blinded EAC will be analyzed. Subjects
who complete or discontinue the trial without having
an outcome will be censored for the relevant analyses
on the last day of follow-up. The primary end point will
be analyzed for the full analysis set and performed using
Cox regression, including only treatment group as a
covariate. The Cox regression model will be used to
estimate the hazard ratio (liraglutide to placebo) and the
2-sided 95% CI. The objective of the LEADER trial is to
assess the cardiovascular safety of liraglutide. Safety will
be established if the two-sided 95% confidence limit is
less than the prespecified upper bound of 1.3, as
established by the United States Food and Drug
Administration. If safety is established, then formal
superiority testing will be performed. Noninferiority of
liraglutide versus placebo will be assessed and estab-
lished if the upper limit is b1.3. If noninferiority is
established for the primary outcome, the data will be
used to test for evidence of a lower outcome hazard
with liraglutide versus placebo. Superiority with respect
to the hazard ratio will be established if the upper range
Figure 2
Enrollment of LEADER trial participants by country. Data presented are number of randomized participants/number of trial sites that randomized
participants by country. In total, 9,340 participants were randomized across 410 active LEADER trial sites. There were 7 sites that screened but did
not enroll or randomize any participants.
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of the two-sided 95% CI is b1. This approach is a closed
testing procedure, and therefore, no adjustment of the
significance level is required.18,19
Exploratory subgroup analyses. The effect of sex,
age (b60 or ≥60 years), body mass index (≤30or N30 kg/
m2), HbA1c (≤8.3 or N8.3%), duration of diabetes (≤11 or
N11 years), region (Europe, North America, Asia, or
other), race (white, black, Asian, or other), cardiovascular
risk, chronic heart failure, severe chronic renal failure,
severe-to-moderate chronic renal failure, and use of
concomitant glucose medication and/or insulin on the
primary composite end point will be explored separately
as a main effect and interaction with treatment by adding
each to the original model.
There will be 2 populations analyzed. The full
analysis set includes all randomized subjects with
evaluation by intention-to-treat, and subjects will be
evaluated as randomized. A sensitivity analysis will be
performed using the per-protocol analysis set that
includes only data from follow-up of subjects exposed
to treatment plus 30 days. Subjects exposed to treatment
in the per-protocol analysis will include those with a
maximum accumulated drug holiday of≤120 days during
the study. Subjects accumulating N120 days will be
Table III. Baseline characteristics of all randomized subjects and by presence of existing CVD
Clinical demographics Previous CVD (n = 7,592) No previous CVD (n = 1,748) Total (N = 9,340)
Age, y 63.9 ± 7.6 65.8 ± 5.2 64.3 ± 7.2
Gender (male) 5,048 (66.5) 955 (54.6) 6,003 (64.3)
Ethnicity
Hispanic or Latino 908 (12.0) 227 (13.0) 1,135 (12.2)
Not Hispanic or Latino 6,684 (88.0) 1,521 (87.0) 8,205 (87.8)
Race
White 5,974 (78.7) 1,263 (72.3) 7,237 (77.5)
Asian 753 (9.9) 169 (9.7) 922 (9.9)
Black 535 (7.0) 240 (13.7) 775 (8.3)
Other 330 (4.3) 76 (4.3) 406 (4.3)
Weight, kg 92.3 ± 20.9 89.6 ± 21.4 91.8 ± 21.0
Body mass index, kg/m2 32.5 ± 6.3 32.4 ± 6.3 32.5 ± 6.3
Hypertension 6,888 (90.7) 1,520 (87.0) 8,408 (90.0)
Hyperlipidemia 6,135 (80.8) 1,056 (60.4) 7,191 (77.0)
Smoking
Current 927 (12.2) 203 (11.6) 1,130 (12.1)
Previous 3,670 (48.3) 667 (38.2) 4,337 (46.4)
Coronary artery disease 5,288 (69.7) 17 (1.0) 5,303 (56.8)
Congestive heart failure 1,562 (20.6) 37 (2.1) 1,599 (17.1)
Peripheral artery disease 1,394 (18.4) 250 (14.3) 1,644 (17.6)
Diabetes duration, y 12.8 ± 8.1 12.3 ± 7.5 12.7 ± 8.0
HbA1c, % 8.7 ± 1.5 8.8 ± 1.6 8.7 ± 1.5
Glucose-lowering therapy
None/diet 405 (5.3) 99 (5.7) 504 (5.4)
Oral antihyperglycemics⁎
1 1,539 (20.3) 378 (21.6) 1,917 (20.5)
2 2,131 (28.1) 555 (31.8) 2,686 (28.8)
≥3 257 (3.4) 71 (4.1) 328 (3.5)
Insulin† 3,260 (42.9) 645 (36.9) 3,905 (41.8)
Aspirin use 5,807 (76.5) 716 (41.0) 6,523 (69.8)
Laboratory Evaluation
Total cholesterol, mg/dL 168.5 ± 45.4 178.8 ± 43.8 170.4 ± 45.3
LDL cholesterol, mg/dL 88.0 ± 35.5 96.5 ± 34.6 89.5 ± 35.5
HDL, mg/dL 44.9 ± 12.1 48.0 ± 12.7 45.5 ± 12.3
Triglycerides, mg/dL 183.5 ± 141.1 177.8 ± 135.0 182.5 ± 140.0
Creatinine, mg/dL 1.0 ± 0.5 0.8 ± 0.2 1.0 ± 0.4
eGFR, mL/min/1.73m2
b30 177 (2.3) 0 177 (1.9)
30-60 1,854 (24.4) 0 1,854 (19.9)
60-90 2,942 (38.8) 918 (52.5) 3,860 (41.3)
N90 2,619 (34.5) 828 (47.4) 3,447 (36.9)
Lipase U/L 48.2 ±45.6 44.9 ± 34.6 47.5 ± 43.7
Amylase U/L 66.5 ± 36.8 64.7 ± 33.7 66.2 ± 36.3
Data presented as number (percentage of group) or mean ± SD.
⁎Not used in combination with insulin.
†Either used alone or in combination with concomitant oral antihyperglycemics.
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considered as having discontinued study drug on the
121st day.
Enrolled population
Enrollment for LEADER commenced in September
2010 and concluded in April 2012. Patients were enrolled
at 410 sites in 32 countries (Figure 2). Baseline de-
mographics of the enrolled population are shown in
Table III. Of the 9,340 patients, 7,592 (81.3%) had prior
CVD and 1,748 (18.7%) did not. There were 1,854
patients with moderate and 177 with severe reductions in
screening eGFR.
Discussion
There remains a compelling need to develop novel,
effective, and safe glucose-lowering therapies for patients
with T2DM. Liraglutide is associated with a reduction in
HbA1c ranging from 1.0 to 1.5%.20 Current dosing of
liraglutide was derived from clinical data aiming to
improve gastrointestinal tolerability while maintaining
efficacy. From this perspective, a starting dose of 0.6 mg
daily is suggested, increasing to 1.2 or 1.8 mg based on
clinical response.
Prior studies have investigated the perceived bene-
ficial effects of GLP-1 receptor agonists on cardiovas-
cular risk. The mechanism of action behind these
effects remains to be clarified. However, there appear
to be a number of direct and indirect effects of
treatment possibly explaining this reduction in risk,
such as significant weight and systolic blood pressure
reduction and, potentially, direct effects on cardiac
myocytes and endothelium.21 A decrease in systolic
blood pressure of 2.1 mm Hg with liraglutide 1.2 mg
and 3.6 mm Hg with 1.8 mg, together with a
sustained mean weight loss of approximately 2 kg,
has been reported.22 In addition, data from 5 long-
term phase 3 trials suggested no adverse impact of
liraglutide treatment on lipid profiles with respect to
cardiovascular risk and favorable changes in triglycer-
ides and free fatty acids. Others have reported
decreases in levels of cardiovascular risk markers
such as plasminogen-activator inhibitor-1 and B-natri-
uretic peptide after treatment.23-25 However, liraglu-
tide is associated with an approximate 1–2 beat/min
increase in heart rate.
Conclusions
LEADER is a phase 3B randomized, double-blind clinical
trial to evaluate the cardiovascular safety of liraglutide in
patients with T2DM at heightened risk for cardiovascular
complications. It is expected that LEADER will provide
conclusive data regarding the cardiovascular safety of
liraglutide relative to standard of care for a global
population of patients with T2DM.
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Appendix
Supplementary Table I. Definitions Used for Clinical Events
Event Definition
Cardiovascular death (occurring
from any of the following):
Sudden, unexpected cardiac cause:
● Cardiac arrest (symptomatic myocardial ischemia, new ST elevation or left bundle branch block,
and/or angiographic or autopsy evidence of new thrombus)
CV cause
● Sudden cardiac death by acute MI, heart failure, stroke, other cardiovascular causes, or no
documented nonvascular cause
Sudden cardiac cause: Unexpected occurrence in a previously stable patient and including:
● Absence of new or worsening symptoms
● Within 60 min of new/worsening symptom onset
● Attributed to identified arrhythmia on ECG or witnessed by emergency medical technicians
● Unsuccessful resuscitation from cardiac arrest or resuscitation but death within 24 h without
noncardiac etiology
● Other cause with information on clinical status within the week preceding death
Acute MI:
● Occurring up to 30 days after documented acute MI and no conclusive evidence of other cause
● Occurring before biomarker confirmation of myocardial necrosis with adjudication based
on clinical presentation and ECG evidence
Other cardiovascular cause
● MI occurring directly from cardiovascular procedures
Heart failure or cardiogenic shock Occurring in the context of clinically worsening
symptoms and/or signs of heart failure without evidence of another cause of death.
New or worsening signs or symptoms without evidence of another cause including:
● Requiring initiation or increase in treatment for heart failure or occurring in a patient on
maximal therapy
● Signs/symptoms requiring continuous intravenous therapy or oxygen administration
● Confinement to bed for heart failure symptoms
● Pulmonary edema sufficient to cause tachypnea and distress not occurring in an acute MI or as
the consequence of arrhythmia without worsening heart failure
● Cardiogenic shock not occurring in an acute MI or from an arrhythmia in the absence of
worsening heart failure. Cardiogenic shock: systolic blood pressure b90 mm Hg N1 h,
unresponsive to fluids or heart rate correction, secondary to cardiac dysfunction and associated
with N1 of the following:
● Cool, clammy skin or
● Oliguria (urine output b30 mL/h)
● Altered sensorium
● Cardiac index b2.2 L min−1 m−2
● SBP ≥90 mm Hg from positive inotropic or vasopressor agents alone and/or with mechanical
support in b1 h, and after randomization.
● Occurring before and continuing after randomization not included
● Sudden death during admission for worsening heart failure.
Cerebrovascular event:
● Intracranial hemorrhagic or nonhemorrhagic stroke occurring up to 30 d and based on
clinical signs and symptoms, neuroimaging or autopsy, and no conclusive evidence of other
cause of death
Other cardiovascular cause
Presumed cardiovascular cause
Not attributed to cardiovascular or noncardiovascular are presumed cardiovascular deaths
Myocardial infarction Any of the following based European Society of Cardiology/American College of Cardiology
Foundation)/American Heart Association/World Heart Federation criteria25:
● Spontaneous MI: Rise and/or fall in cardiac biomarkers with N1 value NULN and
evidence of:
○ Ischemia
○ New ischemia on ECG ST-T changes or left bundle branch block*)
○ Pathological Q waves on ECG†
○ New loss of viable myocardium or regional wall motion abnormality on imaging
● ST-elevation MI: At the J point in 2 contiguous leads (≥0.2 mV in men or ≥0.15 mV in
women in leads V2-V3 and/or ≥0.1 mV in other leads)
(continued on next page)
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● Non–ST-elevation MI: At the J point in 2 contiguous leads (≥0.2 mV in men or ≥0.15 mV
in women in leads V2-V3 and/or ≥0.1 mV in other leads absent on ECG)
● PCI-Related MI: Elevations of cardiac biomarkers N99th percentile upper reference limit
in patients with normal baseline troponin values OR
○ In patients with elevated cardiac biomarkers before PCI, a ≥20% increase in a second
biomarker sample within 24 h of PCI and documented decreasing values before suspected
recurrent MI
● Coronary artery bypass grafting-related mi: Normal baseline troponin values with
elevated cardiac biomarkers N99th percentile URL
○ In patients with elevated cardiac biomarkers before CABG, a ≥20% increase in a second
biomarker sample within 72 h of CABG and documented decreasing values before suspected
recurrent MI and either new pathological Q waves in at least 2 contiguous leads on ECG or new
left bundle branch block, angiographically documented new graft or native coronary artery
occlusion, or loss of viable myocardium on imaging
● Silent MI:
○ No evidence of acute MI AND
New pathological Q waves, evidence a regional loss of viable myocardium on imaging,
evidence of healed or healing MI on autopsy
Cerebrovascular events
(stroke and TIA)
Stroke: Acute neurologic dysfunction documented by CT, MRI, or autopsy and attributed to a
vascular cause and determined to not be due to readily identifiable cause,
Transient ischemic attack b24 h
Micro-hemorrhage: Rounded b5 to 10 mm foci of susceptibility artifact on MRI .
(occurrence not included in the primary event)
Classification of cerebrovascular
events (stroke and TIA)
Transient ischemic attack: Neurological dysfunction caused by focal brain, spinal cord,
or retinal ischemia, without acute infarction.
Ischemic stroke: Acute episode of focal cerebral, spinal, or retinal dysfunction caused
by an infarction of central nervous system tissue
Hemorrhagic stroke: Acute episode of focal or global cerebral, spinal, or retinal dysfunction
caused by a nontraumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage with
documentation of cerebral hemorrhage on imaging or autopsy
Undetermined stroke: Insufficient information to categorize
* ECG manifestations of acute myocardial ischemia (in absence of left ventricular hypertrophy [LVH] and left bundle branch block (LBBB): (1) ST elevation New ST elevation at the J
point in 2 contiguous leads with the cutoff points: ≥0.2 mV in men or ≥0.15 mV in women in leads V2-V3 and/or ≥0.1 mV in other leads. (2) ST depression and T-wave changes New
horizontal or down-sloping ST depression ≥0.05 mV in 2 contiguous leads; and/or T inversion ≥0.1 mV in 2 contiguous leads with prominent R wave or R/S ratio N1.
† Pathological Q waves: (1) Any Q wave in leads V2-V3 ≥0.02 s or QS complex in leads V2 and V3 Q wave ≥0.03 s and ≥0.1 mV deep or QS complex in leads I, II, aVL, aVF, or V4-
V6 in any 2 leads of a contiguous lead grouping (I, aVL, V6; V4-V6; II, III, and aVF).
Supplementary Table I. (continued)
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Supplementary Table II. Other efficacy and safety end points
Time from randomization to first occurrence of a composite microvascular outcome:
● Retinal photocoagulation
● Vitreous hemorrhage
● Diabetes-related blindness
●New or worsening nephropathy (defined as new onset of macroalbuminuria, or doubling of serum creatinine level and eGFR ≤45 mL/min per 1.73m2, or
the need for continuous renal-replacement therapy (in the absence of an acute reversible cause)
● Death due to renal disease
Diabetic foot ulcers
Change from baseline to the last assessment during the treatment period in:
● Weight and waist circumference
● HbA1c
● Blood lipids: total cholesterol, HDL-cholesterol, LDL-cholesterol, and triglycerides
● Blood pressure and pulse rate
● eGFR rate (MDRD and chronic kidney disease-EPI formulas)
● Laboratory parameters:
○ Lipase
○ Amylase
○ Calcitonin
○ Anti liraglutide antibodies
○ ALT
○ Bilirubin (total)
○ Calcium (total)
○ Sodium
○ Potassium
○ Urinary albumin to creatinine ratio
Change from baseline to assessment at 3 y during the treatment period in:
● Weight and waist circumference
● HbA1c
● Blood lipids: total cholesterol, HDL-cholesterol, LDL-cholesterol, and triglycerides
● Blood pressure and pulse rate
● eGFR rate (MDRD and chronic kidney disease-EPI formulas)
● Incidence of hypoglycemic episodes
Incidence of serious adverse events and medical events of special interest:
● Neoplasm
● Pancreatitis
● Acute, severe and persistent abdominal pain leading to a suspicion of pancreatitis
● Acute gallstone disease (biliary colic or acute cholecystitis)
● First confirmed episode of calcitonin concentration increase ≥20 ng/L
● Thyroid disease
● Severe hypoglycemic event
● Immunogenicity event (antibody formation, allergic reactions, immune complex disease and injection site disorders)
● Adverse events leading to treatment discontinuation
Patient reported outcome assessed by EQ-5D questionnaire (in a subset of subjects only)
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Supplementary Table III. Principal Investigators by Country
Steering Committee
J. Buse (Chair) S. Marso (Co-chair)
Canada (B. Zinman);
Denmark (K. Brown Frandsen⁎, M. Stockner⁎, L. Steen Ravn⁎);
Germany (J. Mann, M. Nauck);
United Kingdom (S. Pocock, N. Poulter);
United States (R. Bergenstal, J. Buse, G. Daniels, S. Marso, A. Moses⁎, S.
Nissen, W. Steinberg).
GEP
Australia (R. Simpson),
Austria (T. Pieber);
Belgium (L. Van Gaal);
Brazil (J. Gross, R. Réa);
Canada (L. Berard, L. Leiter);
China (L. Ji, C. Pan);
Czech Republic (M. Haluzik);
Denmark (S. Aggergaard⁎, C. Svendsen⁎, L. Tarnow)
Finland (M. Laakso);
France (M. Marre, F. Travert);
Germany (S. Jacob, J. Lüdemann);
Greece (M. Benroubi);
India (N. Thomas);
Ireland (F. Hayes, D. O'Shea, D. Smith);
Israel (I. Raz);
Italy (E. Mannucci, G. Franco Gensini);
Korea (K. Yoon)
Mexico (M. Arechavaleta Granell);
Netherlands (C. Tack, G. Rutten);
Norway (B. Kilhovd);
Poland (E. Franek, L. Czupryniak);
Romania (M. Mota);
Russia (M. Shestakova);
Serbia (N. Lalic);
South Africa (M. Omar);
Spain (M. Camafort Babkowski);
Sweden (M. Eriksson);
Taiwan (Y. Huang);
Turkey (A. Comlekci, I. Satman);
United Kingdom (S. Bain, J. Petrie);
United Arab Emirates (G. Kaddaha);
United States (R. Pratley, V. Fonseca, M. Warren.
CMC
Denmark (L. Hegedüs);
United States (S. Sherman, M. Tuttle).
DMC
Denmark (A. Flyvbjerg);
Sweden (K. Swedberg);
United Kingdom (P. Sleight, I. Ford);
United States (S. Tenner,R. Kloos).
Participating Institutions
Australia (T. Davis, M. D'Emden, T. Greenaway, R. MacIsaac, M.
McLean, A. Roberts, D. Roberts, K. Sangla, R. Simpson, S. Stranks);
Austria (T. Pieber, R. Prager, G. Schernthaner, T. Wascher);
Belgium (C. Mathieu, J. Ruige, A. Scheen, L. Van Gaal);
Brazil (A. Almeida, R. Baggentoss, A. Bosco, T. Bulcao, A. Chacra, C.
Chrisman, W. Coutinho, F. Eliaschewitz, F. Farias, J. Felício, F. Fraige
Filho, A Forti, B Geloneze. Neto, J. Gross, A. Halpern, M. Hissa, R.
Junior, S. Leite, R. Menezes Filho, E. Niclewicz, D. Panarotto, E.
Quintao, R. Raduan, N. Rassi, R. Rea, G. Rollin, J. Salles, J. Saraiva, J.
Sgarbi, M. Silva, M. Tambascia, S. Vencio, B. Wajchenberg);
Canada (R. Allison, J. Conway, P. DeYoung, F. Dube, I. Gottesman,
S. Harris, I. Hramiak, C. Joyce, L. Leiter, J. Liutkus, R. Rabasa-
Lhoret, E. Raff, T. Ransom, R. Retnakaran, J. Sigalas, S. Weisnagel,
V. Woo);
China (L. JI, C. Pan, Y. Shi, Y. Wang, M. Xu, J. Yang, G. Yuan);
Czech Republic (M. Haluzik, Z. Rusavy);
Denmark (J. Gram, J. Henriksen, K. Hermansen, H. Lervang, S. Madsbad,
L. Tarnow);
Finland (M. Laakso, J. Lahtela, M. Laine, J. Mäkelä, M. Savolainen);
France (M. Marre, C. Petit, D. Richter, M. Rodier);
Germany (H. Clever, M. Esser, A. Hagenow, A. Hinz, S. Jacob, R. Jordan,
H. Kempe, G. Klausmann, W. König, A. König, J. Lüdemann, A. Mölle,
J. Müller, J. Sauter, T. Schaum, A. Segner, O. Sihal, H. Sohn, J.
Steindorf, P. Stübler, R. Tosch-Sisting);
Greece (M. Benroubi, E. Pagkalos, N. Tentolouris);
India (A. Asirvatham, T. Bandgar, M. Baruah, A. Bhansali, T. Chaudhury,
M. Dharmalingam, S. Jain, S. Kalra, J. Kesavadev, H. Kumar, B. Kumar
Sethi, N. Thomas, S. Paramesh, K. Prasana Kumar, V. Mohan, V. Balaji,
S. Vidyasagar);
Ireland (D. O'Shea, D. Smith);
Israel (D. Dicker, J. Ilany, E. Karnieli, O. Minuchin, I. Raz);
Italy (S. Buscemi, R. Buzzetti, A. Ciavarella, A. Consoli, A. Di Carlo, S.
Filetti, E. Mannucci, P. Piatti, G. Sesti);
Republic of Korea (H. Chul Jang, K. Wan Min, Y. Duk Song, J. Taek Woo,
K. Ho Yoon);
Mexico (R. Ruiz, M. Arechavaleta-Granell, E. Muñóz, P. Garcia
Hernandez, G. Gonzalez-Galvez, G. Morales Franco, I. Rodriguez
Briones);
Netherlands (G. Eisma, W. Janssen, A. Kooy, S. Landewe-Cleuren, A.
Lieverse, E. Meesters, G. Rutten, C. Tack);
Norway (J. Cooper, J. Hjelmesæth, B. Kilhovd, B. Kulseng);
Poland (M. Arciszewska, K. Cypryk, M. Dabrowska, T. Dziewit, E. Franek,
G. Gajos, A. Galuszka-Bilinska, M. Konieczny, M. Malecki, M.
Polaszewska-Muszynska, D. Pupek-Musialik, A. Sidorowicz-
Bialynicka, A. Stankiewicz);
Romania (R. Avram, D. Catrinoiu, D. Ciomos, G. Ghise, C. Guja, M. Mota,
E. Pintilei, N. Pletea, I. Szilagyi, A. Vlad);
Russian Federation (I. Dvoryashina, M. Kalashnikova, M. Kunitsyna, T.
Lysenko, G. Reshedko, M. Sergeeva-Kondrachenko, M. Shestakova, M.
Startseva, L. Suplotova, F. Valeeva, E. Voychik, M. Yanovskaya, O.
Zanozina);
Serbia (T. Beljic Zivkovic, N. Lalic, D. Micic, M. Zamaklar;
South Africa (A. Badat, M. Basson, F. Bester, L. Burgess, A. Jacovides, P.
Joshi, J. Kok, S. Komati, D. Lakha, R. Moodley, N. Moosa, M. Omar, S.
Pillay, J. Roos, M. Sarvan, M. Seeber);
Spain (A. Calle Pascual, C. de la Cuesta, S. Duran Garcia, E. Jodar, A.
Marco Mur, L. Comas, P. Raya, E. Romero, E. Sacanella, A. Soto
González);
Sweden (E. Beling, B. Eliasson, M. Eriksson, A. Frid, E. Jasinska, B.
Tengmark);
Taiwan (M. Hsieh, Y. Huang, S. Shin, K. Tien;
Turkey (Y. Altuntas, M. Araz, G. Ayvaz, M. Balci, N. Baskal, A.
Comlekci, T. Damci, T. Erbas, D. Gogas, S. Guler, H. Ilkova, A.
Oguz, M. Sargin, I. Satman, F. Saygili, E. Tuncel, K. Unluhizarci, M.
Yenigun);
United Arab Emirates (G. Kaddaha, F. Alawadi†);
United Kingdom (P. Abraham, K. Adamson, S. Atkin, S. Bain, A. Barnett,
K. Dhatariya, N. Furlong, M. Gibson, A. Jaap,† A. Johnson, S. Kumar,
R. Lindsay, A. Mackie, A. Millward, D. Robertson, D. Russell-Jones, P.
Saravanan, J. Smith, B. Vaidya, M. Yee);
United States (A. Ahmed, L. Akright, O. Alzohaili, M. Amine†, M.
Anderson, L. Aronne, S. Aronoff, S. Asnani, V. Awasty, T. Bailey, D.
Baldwin, M. Barber, O. Barnum, A. Bartkowiak, G. Baula, R. Bergenstal,
B. Bergman, A. Bhargava, R. Blank, R. Bloomberg, D. Brautigam, P.
Bressler, J. Buse, S. Chaidarun, C. Chappel, L. Chaykin, M. Christiansen,
R. Cohen, A. Comulada-Rivera, G. Connor, C. Corder, M. Cromer, S.
Dagogo-Jack, M. Davidson, C. Desouza, K. Devireddy, I. Diab, D.
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Donovan, P. Doshi, D. Eagerton, R. Forbes, E. Franco, R. Garcia, M.
Gilbert, J. Greenwald, G. Grunberger, M. Guice, M. Hamilton, E.
Harris, I. Hartman, K. Hermayer, P. Hollander, J. Hwang, F. Ismail-Beigi,
S. Jabbour, T. Jackson, C. Johnson, M. Juarez, D. Karounos, D.
Kereiakes, A. Khaira, S. Krishnasamy, E. Kwon, J. Labuda, K. Latif, G.
Ledger, J. Lenhard†, M. Leinung, P. Levin, I. Lingvay, R. Looby, K. Lucas,
B. Luna, T. Lyons, M. MacAdams, H. Maheshwari, E. Martin, G.
Martinez, M. May, C. McDaniel, M. McDermott†, J. Menefee, M.
Meredith, B. Miranda-Palma, A. Montgomery, D. Morin†, J. Naidu, I.
Ndukwu, P. Nicol, O. Odugbesan, R. Patel, R. Pratley, R. Purighalla, M.
Quadrel, U. Rangaraj, N. Rasouli, J. Reed, J. Rhudy, L. Rice, J. Risser, A.
Rizvi, J. Rosenstock, A. Samal, J. Sandberg, J. Sandoval, R. Schreiman,
M. Schutta†, B. Seaton, M. Shanik, M. Shomali, R. Silver, A. Sood, K.
Straub, T. Thethi, J. Thrasher, H. Traylor, M. Trevino, B. Villafuerte, M.
Warren, K. Weindorff, P. Winkle, J. Wise, C. Wysham).
⁎Novo Nordisk employee.
†Nonenrolling site.
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